articleTop 1% cited

Key green chemistry research areas—a perspective from pharmaceutical manufacturers

Green Chemistry · 2007 · Vol. 9(5) · pp. 411–420

David J. C. Constable(GlaxoSmithKline (United Kingdom))Peter J. Dunn✉(Pfizer (United Kingdom))John Hayler(GlaxoSmithKline (United Kingdom))Guy R. Humphrey(Merck & Co., Inc., Rahway, NJ, USA (United States))Johnnie L. Leazer(Merck & Co., Inc., Rahway, NJ, USA (United States))Russell J. Linderman(Pfizer (United States))Kurt Lorenz(Eli Lilly (United States))Julie B. ManleyBruce A. PearlmanAndrew S. Wells(AstraZeneca (United Kingdom))A. S. ZaksTony Y. Zhang(Eli Lilly (United States))

View via DOI Publisher page

Abstract

In 2005, the ACS Green Chemistry Institute (GCI) and the global pharmaceutical corporations developed the ACS GCI Pharmaceutical Roundtable to encourage the integration of green chemistry and green engineering into the pharmaceutical industry. The Roundtable has developed a list of key research areas. The purpose of this perspective is to summarise how that list was agreed, provide an assessment of the current state of the art in those areas and to highlight areas for future improvement.

Chemistry and Chemical Engineering Chemical Reaction Mechanisms Chemical Reactions and MechanismsPharmaceutical industryKey (lock)Perspective (graphical)Green chemistryEngineering ethicsBusinessNanotechnologyEngineering managementChemistryEngineering

Citations

1,520

FWCI

26.25

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Direct Nucleophilic S<sub>N</sub>1‐Type Reactions of Alcohols